c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.

@article{Bellon2008cMetIW,
  title={c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.},
  author={Steven F. Bellon and Paula J. Kaplan-Lefko and Yajing Yang and Yihong Zhang and Jodi Moriguchi and Karen Rex and Carol W. Johnson and Paul E Rose and A. M. Long and Anne B O'Connor and Yan Gu and Angela Coxon and Tae-Seong Kim and Andrew Tasker and Teresa L. Burgess and Isabelle Dussault},
  journal={The Journal of biological chemistry},
  year={2008},
  volume={283 5},
  pages={2675-83}
}
c-Met is a receptor tyrosine kinase often deregulated in human cancers, thus making it an attractive drug target. One mechanism by which c-Met deregulation leads to cancer is through gain-of-function mutations. Therefore, small molecules capable of targeting these mutations could offer therapeutic benefits for affected patients. SU11274 was recently described and reported to inhibit the activity of the wild-type and some mutant forms of c-Met, whereas other mutants are resistant to inhibition… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 56 extracted citations

Similar Papers

Loading similar papers…